Cohance Lifesciences share news, announcements and annual reports
NSE: COHANCEBSE: 543064Pharmaceuticals & BiotechnologySmall Cap
Cohance Lifesciences Limited · Formerly Suven Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2020
Last close ₹444.30down ₹37.05 (7.70%)BSE ₹444.45
Share price at the NSE close on 30 Oct 2026. Previous close ₹481.35.
30 Oct: open ₹478.00, high ₹481.30, low ₹442.15
52-week range of traded prices to 30 Oct 2026
₹266.70Low, 9 Mar 2026₹794.75High, 30 Oct 2025
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,999 Cr428th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 160.02
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 133.22
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 4.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,97,28643.3% delivered
Cohance Lifesciences share news and announcements
370 announcements, routine notices left out, newest first. Page 5 of 8.
May 2024
30 May · Results
27 May · Analysts
27 May · Analysts
21 May · Analysts
21 May · Board meeting
Meeting on 30 May 2024: “SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Yearly end”20 May · Analysts
20 May · Board meeting
Mar 2024
20 Mar · Analysts
12 Mar · Rating
Feb 2024
29 Feb · Analysts
29 Feb · Business
29 Feb · Board meeting
29 Feb · Board meeting
24 Feb · Disclosure
5 Feb · Results
Jan 2024
30 Jan · Analysts
29 Jan · Board meeting
12 Jan · Meeting
Dec 2023
21 Dec · Board meeting
Nov 2023
22 Nov · Meeting
10 Nov · Meeting
9 Nov · Updates
9 Nov · Board meeting
9 Nov · Management
9 Nov · Results
2 Nov · Analysts
Oct 2023
20 Oct · Meeting
19 Oct · Public Announcement-Open Offer
11 Oct · Updates
Sep 2023
30 Sep · Management
29 Sep · Management
29 Sep · Management
29 Sep · Board meeting